{"page":{"totalFilteredElements":366},"studies":[{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11855,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-10T08:43:49+01:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11945,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-01T09:33:13+02:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen und verwandter Erkrankungen in Verbindung mit einer prospektiven Biomaterialsammlung","eudractNumber":null,"id":1513,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[],"nctNumber":"NCT02872987","phase":null,"recruitmentStart":"2009-09-15T12:21:43+02:00","shortTitle":"GMALL Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)","eudractNumber":"2022-000760-21","id":7902,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-07-13T08:50:01+02:00","shortTitle":"GMALL-EVOLVE","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA","eudractNumber":"2022-502404-73","id":9114,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05968326","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-11T13:02:42+02:00","shortTitle":"GO44479","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Geriatrisch-onkologische Behandlung und Intervention II<div><br /></div><div>DRKS Registrierungs-Nummer:&#160;00024974</div><div><br /></div><div>Praxisnahe Fortsetzung einer Screening-gest&#252;tzten geriatrisch-onkologischen Behandlung und Intervention (GOBI II) bei vulnerablen &#228;lteren Krebspatienten, die einer ambulanten systemonkologischen oder strahlentherapeutischen Behandlung bed&#252;rfen:&#160;</div><div>Eine monozentrische randomisierte Interventionsstudie.</div><div><br /></div><div>Kurzform: GOBI (Geriatrisch-onkologische Behandlung und Intervention) II</div><div><br /></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":10932,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-01T10:52:07+02:00","shortTitle":"GOBI II","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"GPOH HD Study Registry 2.0<div>Prospective Registry for children and adolescents with classical Hodgkin Lymphoma, nodular lymphocyte-predominant Hodgkin Lymphoma and relapsed Hodgkin Lymphoma<br /><div><br /></div></div>","eudractNumber":null,"id":10077,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-07T13:12:30+02:00","shortTitle":"GPOH HD Study Registry 2.0","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Deutsches MPN-Register und Biomaterialbank f&#252;r BCR-ABL1-negative myeloische Neoplasien<br />","eudractNumber":null,"id":4799,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-19T09:26:07+01:00","shortTitle":"GSG-MPN-Register","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>Deutsches MPN-Register und Biomaterialbank f&#252;r BCR-ABL/-negative<br /></div><div>myeloische Neoplasien</div>","eudractNumber":null,"id":8282,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"},{"id":"leu4","name":"Weitere hämatologische Neoplasien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-04-06T10:17:12+02:00","shortTitle":"GSG-MPN-Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Geriatrisches Register W&#252;rzburg (GRoW)<div><br /></div><div>DRKS00041225</div>","eudractNumber":null,"id":12434,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2026-01-30T09:49:58+01:00","shortTitle":"Geriatric Registry of Würzburg (GRoW)","therapeutical":false,"therapyLines":[]}]}